# Chembio Probability Of Bankruptcy

CEMI | Stock | ## USD 0.81 0.04 4.71% |

Chembio | Probability Of Bankruptcy |

**M**, while Net Income Per Employee is projected to decrease to (103.3

**K**).

## Chembio Probability Of Bankruptcy Analysis

Chembio Diagnostics' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years. 2019 | 2020 | 2021 | 2022 (projected) | |

Revenues USD | 34.46 M | 32.47 M | 47.82 M | 41.89 M |

Revenues | 34.46 M | 32.47 M | 47.82 M | 41.89 M |

Probability Of Bankruptcy | = | Normalized | | Z-Score |

## Current Chembio Diagnostics Probability Of Bankruptcy | 74% |

Most of Chembio Diagnostics' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Chembio Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of Chembio Diagnostics probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Chembio Diagnostics odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Chembio Diagnostics financial health.

Is Chembio Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chembio Diagnostics. If investors know Chembio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chembio Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Market Capitalization 26.3 M | Quarterly Revenue Growth YOY 0.42 | Return On Assets -0.3 | Return On Equity -2.06 |

The market value of Chembio Diagnostics is measured differently than its book value, which is the value of Chembio that is recorded on the company's balance sheet. Investors also form their own opinion of Chembio Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Chembio Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chembio Diagnostics' market value can be influenced by many factors that don't directly affect Chembio Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Chembio Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine Chembio Diagnostics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chembio Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

## Chembio Probability Of Bankruptcy Driver Correlations

Understanding the fundamental principles of building solid financial models for Chembio Diagnostics is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Chembio Diagnostics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Chembio Diagnostics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Chembio Diagnostics' interrelated accounts and indicators.

**Click cells**to compare fundamentals

The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.

Compare to competition |

Based on the latest financial disclosure, Chembio Diagnostics has a Probability Of Bankruptcy of 74%. This is 70.94% higher than that of the Healthcare sector and 81.19% higher than that of the Diagnostics & Research industry. The probability of bankruptcy for all United States stocks is 85.79% lower than that of the firm.

## Chembio Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Chembio Diagnostics' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Chembio Diagnostics could also be used in its relative valuation, which is a method of valuing Chembio Diagnostics by comparing valuation metrics of similar companies.Chembio Diagnostics is currently under evaluation in probability of bankruptcy category among related companies.

## Chembio Diagnostics Main Bankruptcy Drivers

2017 | 2018 | 2019 | 2020 | 2021 | 2022 (projected) | ||

Return on Average Assets | (0.33) | (0.25) | (0.27) | (0.39) | (0.51) | (0.53) | |

Asset Turnover | 1.26 | 1.09 | 0.69 | 0.49 | 0.72 | 0.84 | |

Gross Margin | 0.47 | 0.46 | 0.35 | 0.27 | 0.28 | 0.31 | |

Total Liabilities | 3.54 M | 7.58 M | 31.69 M | 37.12 M | 38.99 M | 42.07 M | |

Current Liabilities | 3.1 M | 6.52 M | 6.44 M | 12.35 M | 15.28 M | 16.49 M | |

Total Assets | 16.62 M | 40.91 M | 55.73 M | 64.89 M | 73.25 M | 58.3 M | |

Current Assets | 10.85 M | 28.45 M | 32.22 M | 39.74 M | 55.23 M | 59.59 M | |

Net Cash Flow from Operations | (5.03 M) | (11.78 M) | (9.06 M) | (18.89 M) | (30.89 M) | (31.7 M) | |

Weighted Average Shares | 12.3 M | 14.43 M | 16.95 M | 19.09 M | 24.3 M | 20.25 M | |

Weighted Average Shares Diluted | 12.3 M | 14.43 M | 16.95 M | 19.09 M | 24.3 M | 20.34 M |

## Chembio Fundamentals

Return On Equity | (153.33) % | |||

Return On Asset | (26.23) % | |||

Profit Margin | (65.95) % | |||

Operating Margin | (43.58) % | |||

Current Valuation | 22.27 M | |||

Shares Outstanding | 30.05 M | |||

Shares Owned by Insiders | 1.31 % | |||

Shares Owned by Institutions | 9.34 % | |||

Number of Shares Shorted | 1.49 M | |||

Price to Earning | (8.49) X | |||

Price to Book | 0.54 X | |||

Price to Sales | 0.45 X | |||

Revenue | 57.91 M | |||

Gross Profit | 12.83 M | |||

EBITDA | (22.4 M) | |||

Net Income | (38.19 M) | |||

Cash and Equivalents | 24.4 M | |||

Cash per Share | 0.81 X | |||

Total Debt | 25.81 M | |||

Debt to Equity | 0.97 % | |||

Current Ratio | 3.54 X | |||

Book Value Per Share | 1.60 X | |||

Cash Flow from Operations | (27.99 M) | |||

Short Ratio | 17.07 X | |||

Earnings Per Share | (1.24) X | |||

Price to Earnings To Growth | (0.03) X | |||

Number of Employees | 337 | |||

Beta | 1.69 | |||

Market Capitalization | 25.84 M | |||

Total Asset | 20.82 M | |||

Retained Earnings | (73.47 M) | |||

Working Capital | 9.48 M | |||

Current Asset | 12.63 M | |||

Current Liabilities | 3.15 M | |||

Z Score | -4.9 |

## About Chembio Diagnostics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Chembio Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chembio Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chembio Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care diagnostic tests that are used to detect or diagnose diseases. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York. Chembio Diagnostics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 337 people.
## Be your own money manager

Our tools can tell you how much better you can do entering a position in Chembio Diagnostics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.## Did you try this?

### Run Portfolio Center Now

## Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios |

All Next | Launch Module |

## Pair Trading with Chembio Diagnostics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Chembio Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Chembio Diagnostics will appreciate offsetting losses from the drop in the long position's value.### Moving against Chembio Diagnostics

0.59 | GTH | Genetron Holdings | Earnings Call This Week | PairCorr | |||

0.51 | ACUR | Acura Pharma Cmn | Earnings Call Today | PairCorr |

The ability to find closely correlated positions to Chembio Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Chembio Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Chembio Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Chembio Diagnostics to buy it.

The correlation of Chembio Diagnostics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Chembio Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Chembio Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Chembio Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Continue to Chembio Diagnostics Piotroski F Score and Chembio Diagnostics Altman Z Score analysis. Note that the Chembio Diagnostics information on this page should be used as a complementary analysis to other Chembio Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

## Complementary Tools for Chembio Stock analysis

When running Chembio Diagnostics price analysis, check to measure Chembio Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chembio Diagnostics is operating at the current time. Most of Chembio Diagnostics' value examination focuses on studying past and present price action to predict the probability of Chembio Diagnostics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Chembio Diagnostics' price. Additionally, you may evaluate how the addition of Chembio Diagnostics to your portfolios can decrease your overall portfolio volatility.

Sync Your BrokerSync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | Go | |

Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities | Go | |

Equity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | Go | |

Money ManagersScreen money managers from public funds and ETFs managed around the world | Go | |

Crypto CorrelationsUse cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | Go | |

Technical AnalysisCheck basic technical indicators and analysis based on most latest market data | Go | |

Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios | Go | |

Sync Your BrokerSync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | Go |

Is Chembio Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chembio Diagnostics. If investors know Chembio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chembio Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Market Capitalization 26.3 M | Quarterly Revenue Growth YOY 0.42 | Return On Assets -0.3 | Return On Equity -2.06 |

The market value of Chembio Diagnostics is measured differently than its book value, which is the value of Chembio that is recorded on the company's balance sheet. Investors also form their own opinion of Chembio Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Chembio Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chembio Diagnostics' market value can be influenced by many factors that don't directly affect Chembio Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Chembio Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine Chembio Diagnostics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chembio Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.